PPS integrates both anatomic disease extent and biological factors, including tumor grade, biomarker status (hormone receptor [HR] status that includes expression of estrogen receptors [ERs] and/or progesterone receptors [PRs] on the surface of tumor cells), human epidermal receptor 2 (HER2) amplification status, and multigene assay results. This evidence concerns the gene NR4A1 and neoplasm.